Company intelligence / Profile preview

Alpha-9 Oncology

Boston, Massachusetts, United Statesa9oncology.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Alpha-9 is advancing a clinical pipeline of radiopharmaceuticals with the first patient dosed in a Phase 1 study of A9-3202 for locally advanced or metastatic melanoma in May 2024. The company has secured significant funding to advance its pipeline.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalsPeptide-based radiopharmaceuticals
Industry: Biotech

Drug pipeline

9 assets

[225Ac]Ac-A9-0642

8 more assets in the full pipeline.

Request access →

Partnerships

ITM Isotope Technologies Munich SENorthStar Medical RadioisotopesActineer Inc.

Beyond the preview

Go deeper on Alpha-9 Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-9 Oncology.

Explore the full profile